Number of the records: 1
Radiolabelled polymeric materials for imaging and treatment of cancer: Quo vadis?
- 1.
SYSNO ASEP 0473653 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Radiolabelled polymeric materials for imaging and treatment of cancer: Quo vadis? Author(s) Pant, K. (DE)
Sedláček, Ondřej (UMCH-V) RID, ORCID
Nadar, R. A. (DE)
Hrubý, Martin (UMCH-V) RID, ORCID
Stephan, H. (DE)Article number 1601115 Source Title Advanced Healthcare Materials. - : Wiley - ISSN 2192-2640
Roč. 6, č. 6 (2017), s. 1-31Number of pages 31 s. Language eng - English Country GB - United Kingdom Keywords polymers ; cancer ; radiodiagnosis Subject RIV FR - Pharmacology ; Medidal Chemistry OECD category Pharmacology and pharmacy R&D Projects GA16-02870S GA ČR - Czech Science Foundation (CSF) GA16-03156S GA ČR - Czech Science Foundation (CSF) NV16-30544A GA MZd - Ministry of Health (MZ) NV15-25781A GA MZd - Ministry of Health (MZ) Institutional support UMCH-V - RVO:61389013 UT WOS 000399717800005 EID SCOPUS 85013367943 DOI https://doi.org/10.1002/adhm.201601115 Annotation Owing to their tunable blood circulation time and suitable plasma stability, polymer-based nanomaterials hold a great potential for designing and utilising multifunctional nanocarriers for efficient imaging and effective treatment of cancer. When tagged with appropriate radionuclides, they may allow for specific detection (diagnosis) as well as the destruction of tumours (therapy) or even customization of materials, aiming to both diagnosis and therapy (theranostic approach). This review provides an overview of recent developments of radiolabelled polymeric nanomaterials (natural and synthetic polymers) for molecular imaging of cancer, specifically, applying nuclear techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Different approaches to radiolabel polymers are evaluated from the methodical radiochemical point of view. This includes new bifunctional chelating agents (BFCAs) for radiometals as well as novel labelling methods. Special emphasis is given to eligible strategies employed to evade the mononuclear phagocytic system (MPS) in view of efficient targeting. The discussion encompasses promising strategies currently employed as well as emerging possibilities in radionuclide-based cancer therapy. Key issues involved in the clinical translation of radiolabelled polymers and future scopes of this intriguing research field are also discussed. Workplace Institute of Macromolecular Chemistry Contact Eva Čechová, cechova@imc.cas.cz ; Tel.: 296 809 358 Year of Publishing 2018
Number of the records: 1